(Q39484903)

12 September 2017

title

Role of arsenic trioxide in acute promyelocytic leukemia (English)

1 reference

12 September 2017

1 reference

0 references

Harry J Iland

1

1 reference

12 September 2017

John F Seymour

series ordinal

2

1 reference

12 September 2017

publication date

1 June 2013

1 reference

Current Treatment Options in Oncology

12 September 2017

published in

1 reference

12 September 2017

volume

14

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

170-184

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-012-0223-3

12 September 2017

exact match

0 references

cites work

Acute promyelocytic leukemia: from highly fatal to highly curable

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Acute Promyelocytc Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

A PMLRARalpha transgene initiates murine acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0223-3

The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion

21 January 2018

1 reference

12 December 2020

Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia.

1 reference

12 December 2020

Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies

1 reference

12 December 2020

A biography of arsenic and medicine in Hong Kong and China.

1 reference

12 December 2020

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients

1 reference

12 December 2020

Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML).

1 reference

12 December 2020

Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group

1 reference

12 December 2020

Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia

1 reference

12 December 2020

Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study

1 reference

12 December 2020

A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

1 reference

12 December 2020

Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines

1 reference

12 December 2020

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

1 reference

12 December 2020

Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation

1 reference

12 December 2020

Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety

1 reference

12 December 2020

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells

1 reference

12 December 2020

Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia

1 reference

12 December 2020

Acute promyelocytic leukemia

1 reference

12 December 2020

The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia

1 reference

12 December 2020

High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia.

1 reference

12 December 2020

Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia

1 reference

12 December 2020

Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia

1 reference

12 December 2020

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity

1 reference

12 December 2020

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

1 reference

12 December 2020

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group

1 reference

12 December 2020

Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia

1 reference

12 December 2020

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal

1 reference

12 December 2020

Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncolo

1 reference

12 December 2020

Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia

1 reference

12 December 2020

Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report

1 reference

12 December 2020

Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study

1 reference

12 December 2020

Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients

1 reference

12 December 2020

Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience

1 reference

12 December 2020

Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups

1 reference

12 December 2020

Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release

1 reference

12 December 2020

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients

1 reference

12 December 2020

1 reference

12 December 2020

Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics [...]

1 reference

12 December 2020

Arsenic trioxide: safety issues and their management

1 reference

12 December 2020

PML protein expression in hematopoietic and acute promyelocytic leukemia cells

1 reference

12 December 2020

10.1007/S11864-012-0223-3

Identifiers

DOI

1 reference

12 September 2017

1 reference